A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Study Identifier
GMA-BTX-CM-12-491
CT.gov Identifier
NCT01749410
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Migraine - Chronic
    • Study Drug
  • onabotulinumtoxinA
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * 15 or more headache days over a 30 day period * A minimum of 7 treatment cycles with onabotulinumtoxinA
    Exclusion Criteria:
    * Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

    Protocol Summary

    This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

    Study Locations

    Location
    Status
    Location
    Encinitas, California, United States
    Status
    Not applicable